Regression to the mean using the disease activity score in eligibility and response criteria for prescribing TNF-α inhibitors in adults with rheumatoid arthritis

Rheumatology

Volumn 46, Issue 7, 2007, Pages 1165-1167

  Greenwood, Mandy C ^a   Rathi, J ^a   Hakim, A J ^a   Scott, D L ^b   Doyle, D V ^a  

^a BARTS HEALTH NHS TRUST   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Clinical guidelines; Disease activity score; Regression to the mean; Rheumatoid arthritis; TNF

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADULT; AGED; ARTICLE; CLINICAL ASSESSMENT; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG EFFICACY; DRUG RESPONSE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; SCORING SYSTEM;

ACUTE DISEASE; ADULT; AGED; AGED, 80 AND OVER; ARTHRITIS, RHEUMATOID; FEMALE; HEALTH STATUS INDICATORS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LINEAR MODELS; MALE; MIDDLE AGED; PATIENT SELECTION; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 34447320793     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kem109     Document Type: Article

References (18)

1. Ledingham J, Deighton C. Update on the British Society for Rheumatology guidelines for prescribing TNFα blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001). Rheumatology 2005;44:157-63.
2. Barnett AG, van der Pols JC, Dobson AJ. Regression to the mean: What it is and how to deal with it. Int J Epidemiol 2005;34:215-20.
3. Bland JM, Altman DG. Regression towards the mean. Br Med J 1994;308:1499.
4. Bland JM, Altman DG. Some examples of regression towards the mean. Br Med J 1994;2005;309:780.
5. Hyrich KL, Watson KD, Silman AJ, Symmons DP. Predictors of response to anti-TNF-{alpha} therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology 2006;45;1558-65.
6. van Vollenhoven RF, Ernestarn S, Harju A, Bratt J, Klareskog L. Etanercept versus etanercept plus methotrexate: A registry-based study suggesting that the combination is clinically more efficacious. Arthritis Res Ther 2003;5:347-51.
7. Emery P, Fleischmann R, Filipowicz-Sosnowska A et al. DANCER study group. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: Results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 2006;54:1390-400.
8. Maini RN, Taylor PC, Szechinski J et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 2006;54:2817-29.
9. Bennett AN, Peterson P, Zain A, Grumley J, Panayi G, Kirkham B. Adalimumab in clinical practice. Outcome in 70 rheumatoid arthritis patients, including comparison of patients with and without previous anti-TNF exposure. Rheumatology 2005;44;1026-31.
10. Wick MC, Ernestarn S, Lindblad S, Bratt J, Klareskog L, van Vollenhoven RF. Adalimumab (Humira) restores clinical response in patients with secondary loss of efficacy from infliximab (Remicade) or etanercept (Enbrel): Results from the STURE registry at Karolinska University Hospital. Scand J Rheumatol 2005;34:353-8.
11. Iannone F, Trotta F, Montecucco C et al. Etanercept maintains the clinical benefit achieved by infliximab in patients with rheumatoid arthritis who discontinued infliximab due to side effects. Ann Rheum Dis. 2007;66:249-62.
12. van der Heijde DM, van't Hof M, van Riel PL, van de Putte LB. Development of a disease activity score based on judgment in clinical practice by rheumatologists. J Rheumatol 1993;20:579-81.
13. Prevoo ML, van't Hof MA, Kuper HH, van Leeuwen MA, van do Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-8.
14. Van der Cruyssen B, Van Looy S, Wyns B et al. DAS28 beat reflects the physician's clinical judgment of response to infliximab therapy in rheumatoid arthritis patients: Validation of the DAS28 score in patients under infliximab treatment. Arthritis Res Ther 2005;7:1063-71.
15. Gardiner PV, Bell AL, Taggart AJ et al. A potential pitfall in the use of the Disease Activity Score (DAS28) as the main response criterion in treatment guidelines for rheumatoid arthritis. Ann Rheum Dis 2005;64:506-7.
16. Mäkinen H, Kautianen H, Hannonen P, Sokka T. Is DAS28 an appropriate tool to assess remisioion in rheumatoid arthritis? Ann Rheum Dis 2005;64;1410-3.
17. Fransen J, Bernelot Moens H, Speyer I, van Riel PLCM. Effectiveness of systematic monitoring of rheumatoid arthritis disease activity in daily practice: A multicentre, cluster randomised controlled trial. Ann Rheum Dis 2005;64:1294-8.
18. den Broeder A, Creemers M, van Gestel A, van Riel P. Dose titration using the disease activity score (DAS28) in rheumatoid arthritis patients treated with anti-TNF-α. Rheumatology 2002;41:638-42.